A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism

BMC Nuclear Medicine

Volumn 1, Issue , 2001, Pages 1-10

  Doi, Suhail A R ^a   Loutfi, Issa ^a   Al Shoumer, Kamal A S ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

ARTICLE; CALCULATION; CONVALESCENCE; DOSIMETRY; DRUG UPTAKE; GRAVES DISEASE; HALF LIFE TIME; HYPOTHYROIDISM; MATHEMATICAL MODEL; MEASUREMENT; NONHUMAN; ORGAN SIZE; RADIATION ABSORPTION; RADIATION DOSE; THYROID GLAND; TREATMENT OUTCOME;

EID: 0002735528     PISSN: 14712385     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2385-1-1     Document Type: Article

References (77)

1. Chapman EM: History of the discovery and early use of radioactive iodine. JAMA 1983, 250:2042-2044
2. Hagen F, Ouelette RP, Chapman EM: Comparison of high and low dosage levels of 131I in the treatment of thyrotoxicosis. N Engl J Med 1967, 277:559-62
3. Cevallos JL, Hagen GA, Maloof F, Chapman EM: Low-dosage 131I therapy of thyrotoxicosis (diffuse goiters). N Engl J Med 1974, 290:141-3
4. Ross DS, Daniels GH, De Stafano P, Maloof F, Ridgway EC: Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983, 57:250-3
5. Glennon JA, Gordon ES, Sawin CT: Hypothyroidism after low-dose I131 treatment of hyperthyroidism. Ann Intern Med 1972, 76:721-3
6. Saito S, Sakurada T, Yamamoto M, Yoshida K, Kaise K, Kaise N, Yoshinaga K: Long term results of radioiodine (131I) therapy in 331 patients with Graves' disease. Tokyo J Exp Med 1980, 132:1-10
7. DeGroot LJ, Mangklabruks A, McCormick M: Comparison of RA 131I treatment protocols for Graves' disease. J Endocrinol Invest 1990, 13:111-118
8. Chapman EM, Maloof F: The use of radioactive iodine in the diagnosis and treatment of hyperthyroidism: Ten years' experience. Medicine 1955, 34:261
9. Blahd W, Hays MT: Graves' disease in the male. A review of 241 cases treated with an individually calculated dose of sodium iodide 131I. Arch Intern Med 1972, 129:33-40
10. Bajnok L, Mezosi E, Nagy E, Szabo J, Sztojka I, Varga J, Galuska L, Leovey A: Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary? Thyroid 1999, 9:865-9
11. Wise PH, Burnet RB, Ahmad A, Harding PE: Intentional radioiodine ablation in Graves' disease. Lancet 1975, 2:1231-3
12. Rajashekharrao B, Nair N: Thyroidal absorbed dose from a standard five-millicurie Iodine-131 (185MBq) dose for thyrotoxicosis: Cure can occur with less than the conventional 7000 rads. J Nucl Med 1991, 32:364-365
13. Hays MT: Hypothyroidism following iodine-131 therapy. J Nucl Med 1982, 23:176-179
14. Okada S: Radiation Biochemistry. Vol 1. Academic Press: New York, NY; 1970247-285
15. Doniach I: In Green MA, Solomon DH (eds) Handbook of physiology. Section 7:Endocrinology Vol III. Thyroid. American Physiological Society, Washington DC, 1974
16. Al-Hindawi AY, Wilson GM: The effect of irradiation on the function and survival of rat thyroid cells. Clin Sci 1965, 28:555-571
17. Walinder G, Sjoden AM: Effect of irradiation on thyroid growth in mouse foetuses and goitrogen challenged adult mice. Acta Radiol Ther Phys Biol 1971, 10:579-592
18. Becker DV, McConahey WM, Dobyns BM, Tomkins E, Sheline GE, Workman JB: The results of radioiodine treatment of hyperthyroidism. A preliminary report of the Thyrotoxicosis Therapy Follow-up Study. In Further Advances in Thyroid Research, Vol 1, Fellinger K and Hofer R (eds) Vienna 1971607
19. Malone JF, Cullen MJ: Two mechanisms for hypothyroidism after 131I therapy. Lancet 1976, 2:73-75
20. Alevizaki CC, Alevizaki-Harhalaki MC, Ikkos DG: Radioiodine-131 treatment of thyrotoxicosis: dose required for and some factors affecting the early induction of hypothyroidism. Eur J Nucl Med 1985, 10:450-454
21. Dunn JT, Chapman EM: Rising Incidence of Hypothyroidism after Radioactive-Iodine Therapy in Thyrotoxicosis N Engl J Med 1964, 271:1037-1042
22. Nygaard B, Hegedus L, Gervil M, Hjalgrim H, Hansen BM, Soe-Jensen P, Hansen JM: Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves disease. J Intern Med 1995, 238:491-497
23. Goolden AWG, Stewart JSW: Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clinical Endocrinology(Oxf) 1986, 24:217-222
24. Verelst J, Bonnyns M, Glinoer D: Radioiodine therapy in voluminous multinodular non-toxic goitre. Acta Endocrinologica (Copenh) 1990, 122:417-421
25. Loevinger R, Holt JG, Hine GJ: Internally administered isotopes in radiation dosimetry. Hine GJ, Brownell GL (eds), Acad Press New York 1956801-875
26. Smith RN, Wilson GM: Clinical trials of different doses of 131I treatment of thyrotoxicosis. Br Med J 1967, 1:129-132
27. Kendall-Taylor P, Keir MJ, Ross WM: Ablative radioiodine therapy for hyperthyroidism: Long-term follow-up study. Br Med J 1984, 289:361-363
28. Blomfield GW, Jones JC, Macgregor AG, Miller H, Wayne EJ, Weetch RS: Treatment of thyrotoxicosis with radioactive iodine. Review of 140 cases. Br Med J 1955, 1:1223-1229
29. Berg GE, Michanek AM, Holmberg EC, Fink M: Iodine-131 treatment of hyperthyroidism: Significance of effective half-life measurements. J Nucl Med 1996, 37:228-232
30. Blahd Wh, Hays MT: Graves disease in the male. Arch Intern Med 1972, 129:33-40
31. Clerc J, Izembart M, Dagousset F, Jais JP, Heshmati HM, Chevalier A, Leger AF, Barritault L: Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole. J Nucl Med 1993, 34:387-93
32. Nagayama Y, Ashizawa K, Matsuo K, Inoue S, Harakawa S, Hirayu H, Yamashita S, Izumi M, Nagataki S: Radioiodine (131I) therapy of Graves' disease: Use of the new high resolutional ultrasonic scanner for the determination of the accurate weight of the thyroid gland. Endocrinol Jpn 1989, 36:359-365
33. Rapoport B, Caplan R, DeGroot L: Low-dose sodium iodide 131I therapy in Graves' disease. JAMA 1973, 224:1610-3
34. Hegedus L, Hansen JEM, Veiergang D, Karstrup S: Thyroid size and goitre frequency in hyperthyroidism. Dan Med Bull 1987, 34:121-123
35. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Radioiodine therapy of Graves' hyperthyroidism: Standard vs. Calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. European J Clin Invest 1995, 25:186-193
36. Willemsen UF, Knesewitsch P, Kreisig T, Pickardt CR, Kirsch CM: Functional results of radioiodine therapy with a 300 Gy absorbed dose in Graves' disease. Eur J Nucl Med 1993, 20:1051-1055
37. Kung AWC, Pun KK, Lam KSL, Choi P, Wang C, Yeung RTT: Long-term results following 131I treatment for Graves disease in Hong Kong chinese - Discriminant factors predicting hypothyroidism. Quart J Med 1990, 76:961-967
38. Blomfield GW, Eckert H, Fisher M, Miller H, Munro DS, Wilson GM: Treatment of thyrotoxicosis with 131I. A review of 500 cases. Br Med J 1959, 1:63-74
39. Tsuruta M, Nagayama Y, Yokoyama N, Izumi M, Nagataki S: Long term followup studies on iodine-131 treatment of hyperthyroid Graves' disease based on measurement of thyroid volume by ultrasonography. Ann Nucl Med 1993, 7:193-197
40. Rapoport B, Caplan R, DeGroot LJ: Low-dose sodium iodide 131I therapy in Graves disease. JAMA 1973, 224:1610-1613
41. Flower MA, Al-Saadi A, Harmer CL, McCready VR, Ott RJ: Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy. Eur J Nucl Med. 1994, 21:531-6
42. Pfeilschifter J, Elser H, Haufe S, Ziegler R, Georgi P: Impact of pretreatment variables on the outcome of standardized 131I therapy with 150 Gray in Graves' disease. Nuklearmedizin 1997, 36:81-86
43. Green M, Wilson GM: Thyrotoxicosis treated by surgery or Iodine-131 with special reference to the development of hypothyroidism. Br Med J 1964, 1:1005-1010
44. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, Buell U: Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab. 1999, 84:1229-33
45. Moser E, Pickardt CR, Mann K, Engelhardt D, Kirsch CM, Knesewitsch P, Tatsch K, Kreisig T, Kurz C, Saller B: Results of radioiodine treatment of patients with immunogenic and non-immunogenic hyperthyroidism using different focal doses. Nuklearmedizin. 1988, 27:98-104
46. Nofal MM, Beierwaltes WH, Patno ME: Treatment of hyperthyroidism with sodium iodide I 131. JAMA 1966, 197:87-92
47. de Bruin TW, Croon CD, de Klerk JM, van Isselt JW: Standardized radioiodine therapy in Graves' disease: the persistent effect of thyroid weight and radioiodine uptake on outcome. J Intern Med 1994, 236:507-513
48. Jarlov AE, Hegedus L, Kristensen LO, Nygaard B, Hansen JM: Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? Clin Endocrinol Oxf 1995, 43:325-329
49. Chen JY, Huang HS, Huang MJ, Lin JD, Juang JH, Huang BY, Wang PW, Liu RT: Outcome following radioactive iodine therapy in Graves' disease. Chang Keng I Hsueh 1990, 13:258-267
50. Bliddal H, Hansen JM, Rogowski P, Johansen K, Friis T, Siersbaek-Nielsen K: 131I treatment of diffuse and nodular toxic goitre with or without antithyroid agents. Acta Endocrinologica 1982, 99:517-521
51. Kalk WJ, Durbach D, Kantor S, Levin J: Very low doses of radioiodine for hyperthyroidism. Failure to prevent a high incidence of early hypothyroidism. South African Med J 1970, 44:479-482
52. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A: Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998, 83:40-6
53. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR: Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab. 1998, 83:685-7
54. Eriksson E, Eriksson K, Wahlberg P: Treatment of hyperthyroidism with standard doses of radioiodine aiming at ablation. Acta Medica Scand 1985, 217:55-60
55. Lowdell CP, Dobbs HJ, Spathis GS, McCready VR, Harmer CL: Low-dose 131I in treatment of Graves' disease. J Royal Soc Med 1985, 78:197-202
56. Nordyke RA, Gilbert FI: Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991, 32:411-416
57. Watson AB, Brownlie BEW, Frampton CM, Turner JG, Rogers TGH: Outcome following standardized 185 MBq dose 131I therapy for Graves' disease. Clinical Endocrinology(Oxf) 1988, 28:487-496
58. Turner J, Sadler W, Brownlie B, Rogers T: Radioiodine therapy for Graves' disease: Multivariate analysis of pretreatment parameters for early outcome. Eur J Nucl Med 1985, 11:191-193
59. Safe AF, Maxwell RT: Efficiency of treatment and monitoring of ablative radio iodine therapy for hyperthyroidism: A DGH centre study Br J Clin Prac 1990, 44:393-395
60. Danaci M, Feek CM, Notghi A, Merrick MV, Padfield PL, Edwards RW: 131-I radioiodine therapy for hyperthyroidism in patients with Graves' disease, uninodular goitre and multinodular goitre. N Z Med J 1988, 101:784-6
61. Johnson JK: Outcome of treating thyrotoxic patients with a standard dose of radioactive iodine. Scott Med J. 1993, 38:142-4
62. Child DF, Mughni MAS, Hudson P, Williams CP, Harvey JN: Hyperthyroidism and radio-iodine therapy in a district general hospital. J R Soc Med 1994, 87:578-580
63. Bringmann IM, van Leeuwen BL, Hennemann G, Beckett GJ, Toft AD: Outcome of treatment of hyperthyroidism. J Endocrinol Invest. 1999, 22:250-6
64. Von Hofe SE, Dorfman SG, Carretta RF, Young RL: The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter. J Nucl Med 1978, 19:180-184
65. Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ: Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med 1984, 311:426-432
66. Roudebush CP, Hoye KE, DeGroot LJ: Compensated low-dose 131I therapy of Graves' disease. Ann Intern Med 1977, 87:441-443
67. Haase A, Bahre M, Lauer I, Meller B, Richter E: Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose. Exp Clin Endocrinol Diabetes 2000, 108:133-7
68. Zaini A, Khir A, Doi SAR, Chan SP, Paramsothy M, Khoo BH: Results of long-term follow-up after compensated fixed-dose therapy for thyrotoxicosis. J Int Med Res 1992, 20:279-288
69. Macgregor AG: Simplified radioactive iodine therapy. Br Med J 1957, 2:492-495
70. Delange F, Bastani S, BenMiloud M: Definitions of endemic goiter and cretinism, classification of goiter size and severity of endemias, and survey techniques. In: Dunn JT, Pretell EA, Daza CH, Viteri FE, eds. Towards the eradication of endemic goiter, cretinism, and iodine deficiency. Washington, DC: Pan American Health Organization, 1986p373-76
71. Stanbury JB, Ermans AM, Hetzel BS, Pretell EA, Querido A: Endemic goitre and cretinism: Public health significance and prevention. WHO Chronicle 1974, 28:220-228
72. Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A: Optimized radioiodine therapy of Graves' disease: Analysis the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol 1999, 141:117-121
73. Kelsy MP, Haines SF, Keating FR: Radioiodine in the study and treatment of thyroid disease. A review. J Clin Endocrinology 1949, 9:171-210
74. Oddie TH: Dosage from radioisotopes uniformly distributed within a sphere. Br J Radiol 1951, 24:333-336
75. Editorial: Protean symptomatology of myxoedema. Br Med J 1970, 3:61-62
76. Berghout A, Wiersinga WM, Smits NJ, Touber JL: The value of thyroid volume measured by ultrasonography in the diagnosis of goitre. Clin Endocrinol Oxf 1988, 28:409-414
77. Hsiao YL, Chang TC: Ultrasound evaluation of thyroid abnormalities and volume in Chinese adults without palpable thyroid glands J Formos Med Assoc 1994, 93:140-4